At the 2026 ESC Congress, Dr. Gerald Watts reported the results of 2 phase 3 trials evaluating plozasiran, an approved FCS therapy, in sHTG.

Updated AHA and ASA guidelines emphasize interprofessional care and inpatient rehabilitation facilities for poststroke recovery.

A new joint scientific statement provides a framework for assessing cardiovascular risk and fitness for duty among tactical athletes.

A virtual reality toolkit may be a feasible intervention for patients that experience anxiety or claustrophobia during PET or CT imaging.

The AAP Committee on Infectious Diseases provides an updated set of recommendations for RSV vaccination among infants and ...

Vutrisiran was associated with favorable cardiac and amyloid changes on imaging in ATTR-CM, according to a recent study.

Semaglutide helps reduce airway exacerbations in patients with chronic obstructive pulmonary disease or asthma.

Arrhythmia-related mortality in patients with congenital heart disease declined overall between 1999 and 2024 despite a recent upward trend.

Laughter therapy and pursed-lip breathing exercises can reduce dyspnea severity and improve overall health status among patients with COPD.

Rusfertide receives FDA approval as a polycythemia vera treatment for adults who do not achieve adequate control through existing therapies.

More advanced cardiovascular-kidney-metabolic syndrome among young adults is associated with worse cardiovascular health.

Integrating machine learning with clinical red flags may help in the diagnosis of patients with suspected hereditary ATTR.